Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Genital Diseases 1Endometrial Neoplasms 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 512Specimen Handling 381Carboplatin 371Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 302Cyclophosphamide 295Radiotherapy 254Paclitaxel 252Biopsy 235Gemcitabine 229Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 154Rituximab 151Fluorouracil 148venetoclax 142atezolizumab 141Docetaxel 141Drug Therapy 140Etoposide 138Doxorubicin 131Ipilimumab 125Radiosurgery 118Lenalidomide 117Prednisone 116Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × serabelisib × 1 year × Clear all
NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡